Legend Biotech Corporation (“Legend Biotech” or the “Company”)
(NASDAQ: LEGN), a global biotechnology company developing,
manufacturing and commercializing novel therapies to treat
life-threatening diseases, today announced the formation of a
strategic advisory board and the appointments of Michel Vounatsos,
former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of
Alnylam Pharmaceuticals, as advisors. Mr. Vounatsos and Dr.
Maraganore will work closely with Legend Biotech’s leadership team
and Board of Directors to advise on strategic initiatives to
advance the Company’s cell therapy platforms.
“We are honored to be joined by such accomplished industry
executives, and we welcome Mr. Vounatsos and Dr. Maraganore to our
advisory board. We look forward to drawing upon their unique global
perspectives and combined experience to help drive the company’s
long-term growth objectives,” said Ying Huang, Legend Biotech’s
CEO.
About Michel Vounatsos
Mr. Vounatsos served as Chief Executive Officer and as a member
of the Board of Directors of Biogen Inc. from January 2017 to
November 2022, shortly after joining the company as Executive Vice
President, Chief Commercial Officer in April 2016.
Prior to joining Biogen, Mr. Vounatsos spent twenty years at
Merck & Co., Inc., where he held a number of leadership roles
in strategy, commercial operations and business development. Most
recently, he served as President, Primary Care and Merck Customer
Centricity, where he led the company’s global primary care
business. While at Merck, Mr. Vounatsos also served as President of
MSD China and held several commercial leadership positions across
Europe. Prior to joining Merck, Mr. Vounatsos held management
positions at Ciba-Geigy, a Swiss pharmaceuticals company that
eventually formed Novartis through its merger with Sandoz Inc.
Mr. Vounatsos currently serves on the Board of PerkinElmer,
Inc., where he is a member of the Audit Committee (March
2020-Present) and Chair of the Nominating and Corporate Governance
Committee (Oct.2022-Present). Mr. Vounatsos also serves on the
Board of Zai Lab (Jan 2023-Present), where he is Chair of the
Commercial Committee and member of the Research and Development
Committee. In addition, he is on the Advisory Board of Tsinghua
University School of Pharmaceutical Sciences, and Chair of
Supervisory Board of LIRYC, the Electrophysiology and Heart
Modeling Institute at the University of Bordeaux.
Mr. Vounatsos obtained his C.S.C.T. certificate in Medicine from
Université Victor Segalen, Bordeaux II, France, and an MBA from HEC
School of Management in Paris.
About John Maraganore, PhD
Dr. Maraganore served as the founding CEO and Director of
Alnylam Pharmaceuticals from 2002-2021, where he led the company
through the approval and global commercialization of the first four
RNA interference therapeutic medicines. At Alnylam, he developed
the company’s value strategy, building over $25 billion in market
capitalization throughout his tenure. He remains a member of the
Alnylam Scientific Advisory Board.
Prior to joining Alnylam, Dr. Maraganore held a number of
leadership roles at Millennium Pharmaceuticals, Inc., across
M&A, strategy, and was responsible for the company’s oncology,
and cardiovascular, inflammatory and metabolic diseases businesses.
Before Millennium, Dr. Maraganore spent ten years at Biogen, Inc.
in a number of business and clinical roles, where he led the
discovery and development of ANGIOMAX® (bivalirudin). Prior to
that, he was a scientist at ZymoGenetics, Inc. and the Upjohn
Company.
Currently, Dr. Maraganore serves as a Venture Partner at Arch
Venture Partners, a Venture Advisor at Atlas Ventures, a Senior
Advisor at Blackstone Life Sciences, Executive Partner at RTW
Investments, and as an Advisor at M28. He is Chair Emeritus of the
Biotechnology Innovation Organization (BIO) and a member of the BIO
board and its Executive Committee. In addition, he serves on the
board of a number of public and private companies: Agios
Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, ProKidney
Corp, Takeda Pharmaceuticals; Aera Therapeutics (Chair), Aerium
Therapeutics, Aitia (Chair), Hemab Therapeutics (Chair), Orbital
Therapeutics (Founder and Executive Chair), and Versanis Bio.
Dr. Maraganore is actively involved with a number of non-profit
organizations committed to the development of future life sciences
leaders and to the advancement of innovative medicines for
patients. He serves on the Board of the Termeer Foundation,
Nucleate, CHDI Foundation, the Advisory Board of n-Lorem and
Ariadne Labs, and is a member of the MGH Research Institute
Advisory Council.
Dr. Maraganore received his BA, MS, and Ph.D. in biochemistry
and molecular biology from the University of Chicago.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to
treating, and one day curing, life-threatening diseases.
Headquartered in Somerset, New Jersey, we are developing advanced
cell therapies across a diverse array of technology platforms,
including autologous and allogeneic chimeric antigen receptor
T-cell and natural killer (NK) cell-based immunotherapy. From our
three R&D sites around the world, we apply these innovative
technologies to pursue the discovery of cutting-edge therapeutics
for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230403005819/en/
Investor Contacts: Joanne Choi, Senior Manager, Investor
Relations, Legend Biotech joanne.choi@legendbiotech.com Crystal
Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com Press Contact: Tina Carter,
Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com (908) 331-5025
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Apr 2023 to Apr 2024